Heart diseases (HDs) represent a major health challenge, being the leading cause of mortality and morbidity worldwide.1 HDs impose a huge economic burden to the healthcare system and the whole society, which is expected to increase due to the growth and aging of the population.2 Hence, safe and effective therapies for HD treatment are highly demanded. However, their development has been mostly limited by pre-clinical testing in poorly predictive in vitro 2D cell cultures and in vivo animal models affected by interspecies differences.3 Limitations in pre-clinical testing also impose safety risks for patients involved in the next clinical trials, which may include impaired cardiac function at different levels up to fatal arrhythmias, ischaemic events, myocardial infarction, and injuries to cardiac valves, the conduction system and the pericardium. In other cases, patient-specific cardiotoxicity risks have been detected only after drug approval causing their withdrawal from the market.4 Notably, drugs developed for other purposes than HD treatment (e.g. chemotherapeutics) also need early cardiotoxicity risk assessment as they may have adverse effects on the heart.
European Research Council-funded grant: development of a novel cardiac tissue model / Ruocco, Gerardina; Testore, Daniele; Chiono, Valeria.. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - ELETTRONICO. - 46:3(2025), pp. 233-235. [10.1093/eurheartj/ehae740]
European Research Council-funded grant: development of a novel cardiac tissue model
Ruocco, Gerardina;Testore, Daniele;Chiono, Valeria.
2025
Abstract
Heart diseases (HDs) represent a major health challenge, being the leading cause of mortality and morbidity worldwide.1 HDs impose a huge economic burden to the healthcare system and the whole society, which is expected to increase due to the growth and aging of the population.2 Hence, safe and effective therapies for HD treatment are highly demanded. However, their development has been mostly limited by pre-clinical testing in poorly predictive in vitro 2D cell cultures and in vivo animal models affected by interspecies differences.3 Limitations in pre-clinical testing also impose safety risks for patients involved in the next clinical trials, which may include impaired cardiac function at different levels up to fatal arrhythmias, ischaemic events, myocardial infarction, and injuries to cardiac valves, the conduction system and the pericardium. In other cases, patient-specific cardiotoxicity risks have been detected only after drug approval causing their withdrawal from the market.4 Notably, drugs developed for other purposes than HD treatment (e.g. chemotherapeutics) also need early cardiotoxicity risk assessment as they may have adverse effects on the heart.File | Dimensione | Formato | |
---|---|---|---|
European Heart Journal - CardioPulse.pdf
accesso riservato
Tipologia:
2a Post-print versione editoriale / Version of Record
Licenza:
Non Pubblico - Accesso privato/ristretto
Dimensione
233.66 kB
Formato
Adobe PDF
|
233.66 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11583/2995362